key: cord-0803447-e18k25ma
authors: Li, Xiaomei; Sun, Jing; Prinz, Richard A.; Liu, Xiufan; Xu, Xiulong
title: Inhibition of porcine epidemic diarrhea virus (PEDV) replication by A77 1726 through targeting JAK and Src tyrosine kinases
date: 2020-06-18
journal: Virology
DOI: 10.1016/j.virol.2020.06.009
sha: 758f60b8676535bdf8286e5458d40ee75c09c177
doc_id: 803447
cord_uid: e18k25ma

Porcine epidemic diarrhea (PED) virus (PEDV) is a coronavirus that primarily infects porcine intestinal epithelial cells and causes severe diarrhea and high fatality in piglets. A77 1726 is the active metabolite of leflunomide, a clinically approved anti-rheumatoid arthritis (RA) drug. A77 1726 inhibits the activity of protein tyrosine kinases (PTKs), p70 S6 kinase (S6K1), and dihydroorotate dehydrogenase (DHO-DHase). Whether A77 1726 can control coronavirus infections has not been investigated. Here we report that A77 1726 effectively restricted PEDV replication by inhibiting Janus kinases (JAKs) and Src kinase activities but not by inhibiting DHO-DHase and S6K1 activities. Overexpression of Src, JAK2 or its substrate STAT3 enhanced PEDV replication and attenuated the antiviral activity of A77 1726. Our study demonstrates for the first time the ability of A77 1726 to control coronavirus replication by inhibiting PTK activities. Leflunomide has potential therapeutic value for the control of PEDV and other coronavirus infections.

Porcine epidemic diarrhea (PED) virus (PEDV) is an important pathogen that primarily infects the villous gastrointestinal epithelial cells of pigs. The main symptoms of PEDV infection are severe vomiting, watery diarrhea, and dehydration (Chen et al., 2014; Song and Park, 2012) . The disease was first reported in Europe in 1960 and in Japan in 1982. PED rapidly spread to its neighboring countries, particularly South Korea and China. PEDV evolved in late 2010 has since caused large scale epizootics in China and many other Asian countries including South Korea, Thailand, Philippines, and Vietnam (Chen et al., 2014; Song and Park, 2012) . Newly emerging PEDV strains are highly pathogenic, incurring an 80-100% fatality in piglets (Chen et al., 2014; Song and Park, 2012) . CV777，a vaccine used in the 1990s, has been losing its efficacy in preventing newly emerged PEDV strains. PED was exotic in the United States until 2013. PED outbreaks then rapidly spread throughout the country and has caused severe economic losses to the pig industry (Vlasova et al., 2014) . The virus initially isolated in the United States shares a great homology with PEDV strains that have reemerged in China. Live attenuated or killed vaccines have been developed in Asia and the United States. These vaccines have provided limited protection and sometimes are not safe. There has been increasing interest in developing antiviral drugs for the control of PEDV infections.

PEDV is a member of the α genera of the Coronaviridae family (Fehr and Perlman, 2015) .

The virus contains a single-stranded positive-sense RNA genome of approximately 28 kb (Beall et al., 2016) . Approximately two-third of its genome encodes two open reading frames (ORF1a and ORF1b) that function as an RNA polymerase for duplicating the virus genome and viral gene transcription (Beall et al., 2016) . The remaining portion of the PEDV genome encodes a non-structural protein (ORF3) and four structural proteins, including envelope (E), membrane (M), nucleocapsid(N), and spike-like protein (S) (Beall et al., 2016) . These proteins are assembled into virions and play important roles in virus entry into the host cells and the induction of antiviral immunity (Beall et al., 2016) . PEDV primarily infects the porcine villous gastrointestinal epithelial cells or enterocytes. PEDV infection leads to activation of the epidermal growth factor receptor (EGFR) and its downstream transcription factor STAT3 (Yang et al., 2018) . Inhibition of EGFR or STAT3 by siRNA or their specific inhibitors leads to increased expression of antiviral interferons and decreased PEDV replication (Yang et al., 2018) . In addition to being phosphorylated and activated by EGFR, STAT3 is phosphorylated at Tyr 705 by the cytokine receptor-activated Janus kinases (JAKs) and by Src tyrosine kinase (Bowman et al., 2000) . Recent studies have shown that JAKs play important roles in promoting virus replication (Eierhoff et al., 2010; Gavegnano et al., 2017; Gavegnano et al., 2014; Han et al., 2018; Watanabe et al., 2014) . For example, JAK1 and JAK2 have been recently identified as novel cellular factors that are crucial for influenza A virus and HIV replication (Eierhoff et al., 2010; Gavegnano et al., 2017; Gavegnano et al., 2014; Han et al., 2018; Watanabe et al., 2014) . Whether targeting JAK and Src could lead to the suppression of coronavirus replication remains to be investigated.

Leflunomide is an anti-inflammatory drug primarily used for treating rheumatoid arthritis.

After ingestion, leflunomide is quickly converted in the liver and gastrointestinal tract (Fig. 1A) into its active metabolite, A77 1726 (Breedveld and Dayer, 2000) . We and others have reported earlier that A77 1726 is able to inhibit the activity of several protein tyrosine kinases (PTKs), including platelet-derived growth factor receptor (PDGF), JAK1, JAK3, and two Src family tyrosine kinases (p56 lck and p59 fyn ) (Elder et al., 1997; Ruckemann et al., 1998; Siemasko et al., 1998; Siemasko et al., 1996; Xu et al., 1997; Xu et al., 1999; Xu et al., 1995; Xu et al., 1996) . Later studies showed that A77 1726 also inhibits the activity of DHO-DHase, a rate-limiting enzyme in de novo pyrimidine nucleotide synthesis (Ruckemann et al., 1998; Williamson et al., 1996; Xu et al., 1997; Xu et al., 1999; Xu et al., 1996) . Recently, our lab discovered a third molecular target of A77 1726. It inhibits the activity of p70 S6 kinase 1 (S6K1), a serine/threonine kinase in the PI-3 kinase pathway. Doscas et al., 2014; Sun et al., 2018; Xu et al., 2017) . A77 1726 inhibits the activity of S6K1 and PTKs in an in vitro kinase assay and in cell culture with the IC 50 values of 50-75 µM (Doscas et al., 2014; Xu et al., 1995; Xu et al., 1996) but inhibits the activity of DHO-DHase more potently, with an IC 50 value in the nano-to micromolar range (Ruckemann et al., 1998; Williamson et al., 1996; Xu et al., 1996) .

Numerous studies have shown that A77 1726 possesses some strong antiviral activities.

For example, A77 1726 inhibits the replication of BK virus (Bernhoff et al.; Liacini et al., 2010) and cytomegalovirus (CMV) (Chacko and John, 2012; Waldman et al., 1999a; Waldman et al., 1999b) , two types of viruses that cause graft rejection in immunosuppressed transplant patients. The antiviral activity of leflunomide has been validated in transplant patients infected with CMV and BK (Chacko and John, 2012) . A77 1726 also inhibits the replication of several other virus types, including herpes simplex type 1 virus (Knight et al., 2001) , and Epstein-Barr virus (EBV) (Bilger et al., 2017) , hepatitis E virus (HEV) , and rotavirus . Because A77 1726 hits multiple molecular targets, how A77 1726 exerts its antiviral effects remain controversial.

Our present study focused on the ability of A77 1726 to control PEDV replication and its underlying mechanisms. Here we report that A77 1726 suppressed PEDV replication by inhibiting the activity of JAK and Src.

A77 1726 . HXLV and CAJ, two highly pathogenic PEDV isolates, were kindly provided by Liyuan Biotechnology Inc., Nanning, Guanxi Province, China.

HLJBY strain, a PEDV isolate with low pathogenicity, has been recently reported (Huan et al., 2019) .

The virus was propagated in Vero cells in the presence of 8 µg/ml TPCK trypsin (8 µg/ml) during and after virus inoculation. The virus titers were measured by a 10-fold serial dilution (10 -1 to 10 -5 ), each dilution was inoculated into Vero cells. The 50% tissue culture infection dose (TCID 50 /0.1 ml) was 

We first determined the inhibitory effect of A77 1726 on viral protein synthesis. HLJBY virus is a strain isolated in 2011 from a piglet with diarrhea from Helongjiang province, China. HLJBY virus has low pathogenicity that is comparable to CV777, a PEDV vaccine strain (Huan et al., 2019) . This strain can readily replicate in Vero cells and in IPEC-DQ cells, a subline that was derived from IPEC-J2 cells, a porcine intestinal epithelial cell line . normal levels by exogenous uridine Xu et al., 1996) . To determine if the antiviral activity of A77 1726 was mediated by inhibition of pyrimidine nucleotide synthesis, we tested if excessive uridine added to the culture media of PEDV-infected cells could ablate the antiviral effect of A77 1726. As shown in Fig. 1A -C, A77 1726 was still able to dose-dependently reduce the N and S protein levels in the cells infected with two strains of PEDV in the presence of uridine (200 µM).

The titers of the HLJBY virus in IPEC-DQ cells were too low to be detected (data not shown). Evidence that A77 1726 inhibits PEDV replication independent of its activity on DHO-DHase and S6K1. Having shown the inability of uridine to neutralize the antiviral activity of A77 1726, we then tested if BQR, a potent DHO-DHase inhibitor, was also unable to inhibit PEDV replication. As shown in Fig. 2A , BQR used up to 20 µM, a very high concentration since its IC 50 value to inhibit DHO-DHase activity is at least 10-fold lower than that of A77 1726, had little effect on viral N and S protein synthesis. We next determined if inhibition of S6K1 activity by A77 1726 could contribute to its antiviral activity by investigating the ability of PF-4708671, a specific and potent inhibitor of S6K1, to inhibit PEDV replication. PF-4708671 up to 20 µM did not significantly decrease viral N and S protein levels ( Fig. 2B ). PF-4708671 decreased S6 phosphorylation but increased S6K1 and AKT phosphorylation due to feedback activation of the PI-3 kinase pathway (Fig.   2C ), a well-established phenomenon for S6K1 inhibitor (Pearce et al., 2010) . Neither BQR nor PF-4708671 significantly caused cytotoxicity in Vero cells in the absence or presence of PEDV infection ( Fig. 2D & E) .

Since inhibition of DHO-DHase and S6K1 activities by their specific inhibitors did not significantly inhibit PEDV replication, A77 1726 likely inhibited PEDV replication by inhibiting the activity of PTKs. Our prior studies have shown that A77 1726 inhibits the JAK and Src family PTK activities (Elder et al., 1997; Siemasko et al., 1998; Xu et al., 1995) . Here we tested if SU6656 and Ruxolitinib (Rux), specific inhibitors of Src and JAK tyrosine kinases, respectively, were able to inhibit PEDV replication. SU6656 decreased the levels of the S and N proteins of PEDV in Vero cells (Fig. 3A ) and virus titers in the conditioned media (Fig.   3C ). SU6656 inhibited Src tyrosine phosphorylation in uninfected Vero cells in a dose-dependent manner (Fig. 3A) . Rux dose-dependently decreased the levels of the S and N proteins (Fig. 3B) and decreased the titers of PEDV (Fig. 3D) 5A ). STAT3 overexpression significantly increased total and phosphorylated STAT3 in IPEC-DQ cells but did not affect JAK2 phosphorylation and total JAK2 protein levels (Fig. 5B) . STAT3

overexpression accelerated viral N protein synthesis (Fig. 5B) , suggesting that STAT3 phosphorylation can accelerate PEDV replication.

Finally, we determined if overexpression of a constitutively activated Src, JAK2, or STAT3 gene in Vero cells could enhance PEDV replication and compromise the antiviral activity of A77 1726.

As shown in Fig. 6A 1726-treated cells overexpressing JAK2, STAT3, or Src were significantly higher than their corresponding counterparts in pcDNA3.1-transfected Vero cells (Fig. 6D-F ).

Our present study shows that A77 Waldman et al., 1999b), and herpes simplex type 1 virus (Knight et al., 2001) independent of its inhibitory effect on pyrimidine nucleotide biosynthesis. Our present study showed that uridine was unable to reverse A77 1726-mediated inhibition of PEDV replication and that BQR, a potent DHO-DHase inhibitor, was unable to suppress PEDV replication. These observations collectively suggest that A77 1726-mediated antiviral activity against PEDV is independent of its inhibitory effect on pyrimidine nucleotide synthesis. The notion that A77 1726 restricted PEDV replication not by inhibiting pyrimidine nucleotide synthesis is strengthened by the observations that leflunomide is the only DHO-DHase inhibitor capable of controlling virus replication in vivo (Waldman et al., 1999a; Waldman et al., 1999b) . Other DHO-DHase inhibitors do not have any in vivo antiviral activities due to the presence of serum uridine that can be used to synthesize pyrimidine nucleotides by a salvage pathway Hoffmann et al., 2011; Wang et al., 2011) .

It is puzzling why inhibition of pyrimidine nucleotide synthesis is responsible for the antiviral activity of A77 1726 towards certain types of viruses but not others. We speculate that, the ability of A77 1726 to restrict virus replication by inhibiting pyrimidine nucleotide synthesis depends on how fast a virus replicates and how fast the cells used to propagate this virus proliferate. When the fast proliferating tumor cell lines used to grow viruses are plated in a low density, tumor cell proliferation and virus replication consume a large amount of nucleotides that could quickly deplete intracellular nucleotide pools in the absence of a DHO-DHase inhibitor. However, when the cells used to grow viruses are plated at a high density and are less proliferative, inhibition of DHO-DHase activity will not deplete pyrimidine nucleotide pools, virus replication will not be inhibited. In our experiment, Vero and IPEC-DQ cells, an immortalized noncancerous cell line , were plated at a high density. Following virus inoculation, the cells were incubated in the absence of serum.

Virus replication was analyzed from 12 to 24 hr.

The STAT family transcription factors have been implicated in playing an important role in regulating antiviral innate immunity. Recent studies have shown that coronaviruses evade antiviral immunity by modulating STAT activity and protein stability. Zhu et al. (Zhu et al., 2017) reported that the nsp5 protease of porcine deltacoronavirus cleaves STAT2 and interferes with the interferon signaling pathway, leading to the suppression of the expression of the interferon stimulating genes (ISGs). Likewise, Guo et al. (Guo et al., 2016) reported that PEDV infection induces ubiquitin-proteasome degradation of STAT1, leading to the downregulation of IFN-mediated response. Unlike STAT1 and STAT2, the role of STAT3 in virus replication appears to be very complex (Chang et al., 2018; Kuchipudi, 2015; Roca Suarez et al., 2018) . STAT3 can be positively or negatively regulated by different virus types and plays a pro-and antiviral role in virus replication (Kuchipudi, 2015) (Chang et al., 2018) . Yang et al (Yang et al., 2018) (Shin et al., 2018) .

Saracatinib, a Src family tyrosine kinase inhibitor, inhibits the early stages of the MERS-CoV life cycle (Shin et al., 2018) . JAKs may also promote virus endocytosis by regulating the cycling G-associated kinase (GAK) (Richardson et al., 2020) . p59 Fyn , a member of the Src family tyrosine kinase, participates in viral RNA replication and virion assembly and/or secretion of the dengue virus (de Wispelaere et al., 2013) . Recent studies have shown that JAK1 and JAK2 are required for influenza A virus (IAV) replication (Han et al., 2018; Watanabe et al., 2014) . JAK1 plays an important role in virion assembly of IAV (Watanabe et al., 2014) . Our recent study showed that A77

1726 inhibits IAV replication in vitro and in vivo by targeting JAK2 (Wang et al., 2020) . In addition, PTKs may activate the MAP kinase pathway to promotes virus replication (Shin et al., 2018) . Our preliminary study showed that addition of A77 1726 to Vero cells 2 hr post inoculation and to IPEC-DQ cells 12 post inoculation was able to inhibit PEDV replication (data not shown), suggesting that A77 1726 blocks a step in the late stage of the viral life cycle. How inhibition of JAK and Src tyrosine kinase activity by A77 1726 decreases PEDV replication remains elusive.

Coronavirus infections pose a great threat to human and animal health. Among them, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses are highly contagious and often fatal (Hilgenfeld and Peiris, 2013; Hui et al., 2020; Lu et al., 2020; Zhang et al., 2020a; Zumla et al., 2016) . SARS-CoV2, a novel coronavirus in the β genera of the coronaviridae family and the etiological agent that causes a worldwide pandemic currently, has infected more than four million individuals worldwide and caused hundreds of thousands of deaths. Currently, there are no effective antiviral drugs for treating coronavirus infections in humans and animals (Zumla et al., 2016) . Remdesivir, a monophosphoramidate prodrug of an adenosine analogue with broad spectrum antiviral activities on filoviruses, paramyxoviruses, pneumoviruses, and coronaviruses, has been recently approved by the Food and Drug Administration for emergency use to treat COVID-19 (Ledford, 2020) . There has been great interest in developing novel antiviral agents by targeting crucial host factors required for virus replication (Hilgenfeld and Peiris, 2013) . In the present study, we provide evidence that A77 1726 effectively suppressed PEDV replication by inhibiting JAK and Src tyrosine kinase activities. Our study uncovers a previously unrecognized mechanism of action of A77 1726-mediated antiviral effects. Leflunomide, a clinically approved anti-inflammatory drug, could be potentially repurposed for the control of coronavirus infections by inhibiting virus replication and by alleviating severe inflammation in virus-infected tissues. Remarkably, JAK inhibitors are currently being tested in clinical trials for the control of the cytokine storm in COVID-19 patients (Mehta et al., 2020; Richardson et al., 2020; Russell et al., 2020; Zhang et al., 2020b) . Since the antiviral activity of A77 1726 has been well documented, leflunomide may hold great advantages over other JAK inhibitors.

However, great cautions should be taken since leflunomide is an immunosuppressant and has numerous side-effects such as diarrhea and hepatic toxicity. These side-effects may exacerbate the symptoms of COVID-19 patients and complicate its use.

Whether leflunomide can be used as an antiviral drug to treat PEDV infections in piglets remains to be investigated. The concentrations of A77 1726 in the plasma of mice treated with leflunomide (35 mg/kg/day) and in RA patients treated with leflunomide (100 mg per day for three days, 20 mg daily later) reach over 500 and 200 µM, respectively (Chan et al., 2005; Chong et al., 1999) . Leflunomide has been shown to be effective in suppressing virus replication in animal models and in transplant patients (Chacko and John, 2012) . If leflunomide is indeed capable of suppressing PEDV replication in pigs, it could be potentially useful for PED prophylaxis and treatment. Leflunomide, a small-molecule drug that can be manufactured at a low cost for veterinary use, should be practical for treating PED in piglets. 

Characterization of a Pathogenic Full-Length cDNA Clone and Transmission Model for Porcine Epidemic Diarrhea Virus Strain PC22A

Leflunomide inhibition of BK virus replication in renal tubular epithelial cells

Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication

Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV)

STATs in oncogenesis

Leflunomide: mode of action in the treatment of rheumatoid arthritis

Leflunomide for cytomegalovirus: bench to bedside

Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis

STAT3 roles in viral infection: antiviral or proviral?

Control of hyperglycemia in male mice by leflunomide: mechanisms of action

Isolation and characterization of porcine epidemic diarrhea viruses associated with the 2013 disease outbreak among swine in the United States

Suppression of pyrimidine biosynthesis by targeting DHODH enzyme robustly inhibits rotavirus replication

In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression

The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase

Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress

The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells

The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms

NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer

Coronaviruses: an overview of their replication and pathogenesis

Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors

Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro

Porcine Epidemic Diarrhea Virus Infection Inhibits Interferon Signaling by Targeted Degradation of STAT1

Genome-wide CRISPR/Cas9 Screen Identifies Host Factors Essential for Influenza Virus Replication

From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses

Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis

Characterization and evolution of the coronavirus porcine epidemic diarrhoea virus HLJBY isolated in China

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan

Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide

The Complex Role of STAT3 in Viral Infections

Hopes rise for coronavirus drug remdesivir

Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection

Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle

Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis

COVID-19: consider cytokine storm syndromes and immunosuppression

On dihydroorotate dehydrogenases and their inhibitors and uses

Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Viral manipulation of STAT3: Evade, exploit, and injure

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans

Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence

Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro

Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production

Regulation of B cell function by the immunosuppressive agent leflunomide

Porcine epidemic diarrhoea virus: a comprehensive review of molecular epidemiology, diagnosis, and vaccines

Inhibition of p70 S6 kinase activity by A77 1726 induces autophagy and enhances the degradation of superoxide dismutase 1 (SOD1) protein aggregates

Distinct characteristics and complex evolution of PEDV strains

Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide

Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide

A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of

Inhibition of dengue virus through suppression of host pyrimidine biosynthesis

Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication

Influenza virus-host interactome screen as a platform for antiviral drug development

Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide

In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice

In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action

Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation

Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide

Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation

Porcine Epidemic Diarrhea Virus-Induced Epidermal Growth Factor Receptor Activation Impairs the Antiviral Activity of Type I Interferon

Role of c-Jun terminal kinase (JNK) activation in influenza A virus-induced autophagy and replication

Recent advances in the detection of respiratory virus infection in humans

Type III Interferon Restriction by Porcine Epidemic Diarrhea Virus and the Role of Viral Protein nsp1 in IRF1 Signaling

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

Porcine Deltacoronavirus nsp5 Antagonizes Type I Interferon Signaling by Cleaving STAT2

Coronaviruses -drug discovery and therapeutic options